- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
The EGFR receptors are a family of four membrane-bound receptor tyrosine kinases (RTK), including EGFR, HER2, HER3, HER4. In many cancers, such as NSCLC, members of the EGFR family are often overexpressed and can provide an oncogenic signal: dysregulation and overexpression of various EGFRs have been associated with a wide variety of tumour types. A variety of mechanisms leading to constitutive activation of this key signal transduction pathway have been described and comprise:
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
